Dyne Therapeutics (DYN) Competitors $14.41 -0.05 (-0.35%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$14.40 -0.01 (-0.03%) As of 06/13/2025 04:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DYN vs. LEGN, TGTX, GRFS, LNTH, TLX, NUVL, AXSM, ADMA, PCVX, and AKROShould you be buying Dyne Therapeutics stock or one of its competitors? The main competitors of Dyne Therapeutics include Legend Biotech (LEGN), TG Therapeutics (TGTX), Grifols (GRFS), Lantheus (LNTH), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Nuvalent (NUVL), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry. Dyne Therapeutics vs. Its Competitors Legend Biotech TG Therapeutics Grifols Lantheus Telix Pharmaceuticals Limited American Depositary Shares Nuvalent Axsome Therapeutics ADMA Biologics Vaxcyte Akero Therapeutics Dyne Therapeutics (NASDAQ:DYN) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, community ranking, analyst recommendations and profitability. Do analysts prefer DYN or LEGN? Dyne Therapeutics presently has a consensus price target of $44.93, suggesting a potential upside of 211.79%. Legend Biotech has a consensus price target of $76.20, suggesting a potential upside of 106.90%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than Legend Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 3.00Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Does the MarketBeat Community prefer DYN or LEGN? Legend Biotech received 43 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 79.03% of users gave Dyne Therapeutics an outperform vote while only 73.02% of users gave Legend Biotech an outperform vote. CompanyUnderperformOutperformDyne TherapeuticsOutperform Votes4979.03% Underperform Votes1320.97% Legend BiotechOutperform Votes9273.02% Underperform Votes3426.98% Which has higher valuation & earnings, DYN or LEGN? Dyne Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$235.94M-$3.59-4.01Legend Biotech$728.30M9.29-$518.25M-$0.59-62.42 Do institutionals & insiders have more ownership in DYN or LEGN? 96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 14.1% of Dyne Therapeutics shares are owned by company insiders. Comparatively, 0.0% of Legend Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to DYN or LEGN? In the previous week, Legend Biotech had 8 more articles in the media than Dyne Therapeutics. MarketBeat recorded 14 mentions for Legend Biotech and 6 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.03 beat Legend Biotech's score of 0.69 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DYN or LEGN more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Legend Biotech's return on equity of -29.69% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -57.46% -51.62% Legend Biotech -66.92%-29.69%-19.45% Which has more volatility & risk, DYN or LEGN? Dyne Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. SummaryDyne Therapeutics beats Legend Biotech on 12 of the 18 factors compared between the two stocks. Get Dyne Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DYN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DYN vs. The Competition Export to ExcelMetricDyne TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.64B$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E Ratio-4.058.4626.7519.66Price / SalesN/A261.91403.98152.07Price / CashN/A65.8538.2534.64Price / Book9.676.526.964.59Net Income-$235.94M$143.26M$3.23B$248.23M7 Day Performance-1.97%-0.21%-1.22%-1.07%1 Month Performance22.74%10.62%6.34%2.59%1 Year Performance-56.43%3.63%33.05%13.50% Dyne Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DYNDyne Therapeutics2.4385 of 5 stars$14.41-0.3%$44.93+211.8%-56.4%$1.64BN/A-4.05100Positive NewsAnalyst ForecastGap DownLEGNLegend Biotech3.0816 of 5 stars$34.78-0.6%$76.20+119.1%-13.2%$6.39B$728.30M-36.611,070Short Interest ↑Analyst RevisionGap DownTGTXTG Therapeutics3.5298 of 5 stars$39.84-0.5%$40.80+2.4%+117.6%$6.32B$386.39M-398.36290Positive NewsAnalyst RevisionGap DownGRFSGrifols3.5618 of 5 stars$8.83+0.1%N/A+26.7%$6.07B$7.21B7.5526,300Gap DownLNTHLantheus4.3227 of 5 stars$83.22+2.0%$132.67+59.4%-1.8%$5.76B$1.54B13.85700TLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.91+0.8%$22.00+30.1%N/A$5.72B$783.21M0.00N/ANews CoverageAnalyst ForecastGap DownNUVLNuvalent2.3389 of 5 stars$76.08-2.5%$115.50+51.8%+0.6%$5.46BN/A-21.9340AXSMAxsome Therapeutics4.7308 of 5 stars$109.87-1.8%$172.80+57.3%+41.4%$5.41B$432.16M-18.34380Trending NewsAnalyst ForecastInsider TradeAnalyst RevisionADMAADMA Biologics2.3447 of 5 stars$20.87+1.3%$24.25+16.2%+95.8%$4.98B$459.38M74.54530Positive NewsInsider TradeAnalyst RevisionPCVXVaxcyte3.161 of 5 stars$37.20+0.6%$136.50+266.9%-52.6%$4.80BN/A-8.09160Positive NewsAnalyst RevisionGap DownAKROAkero Therapeutics3.6098 of 5 stars$54.71+0.8%$82.50+50.8%+131.9%$4.36BN/A-14.5930Trending NewsInsider TradeHigh Trading Volume Related Companies and Tools Related Companies Legend Biotech Competitors TG Therapeutics Competitors Grifols Competitors Lantheus Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors Nuvalent Competitors Axsome Therapeutics Competitors ADMA Biologics Competitors Vaxcyte Competitors Akero Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DYN) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dyne Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dyne Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy DYN Stock Free DYN Stock Alerts